^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DLL4 inhibitor

    Related drugs:
    5ms
    COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=49, Completed, Compass Therapeutics | Active, not recruiting --> Completed | N=84 --> 49
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    tovecimig (CTX-009)
    9ms
    COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=84, Active, not recruiting, Compass Therapeutics | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    tovecimig (CTX-009)
    10ms
    CTX-009 with Gemcitabine, Cisplatin, and Durvalumab As First-line Therapy in Patients with Unresectable or Metastatic Biliary Tract Cancers (clinicaltrials.gov)
    P1/2, N=50, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • tovecimig (CTX-009)
    10ms
    A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients (clinicaltrials.gov)
    P1/2, N=41, Terminated, Handok Inc. | N=92 --> 41 | Trial completion date: Jul 2025 --> Jan 2025 | Active, not recruiting --> Terminated; Change of Development Plan
    Enrollment change • Trial completion date • Trial termination
    |
    paclitaxel • irinotecan • tovecimig (CTX-009)
    over1year
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=150, Active, not recruiting, Compass Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    paclitaxel • tovecimig (CTX-009)
    over1year
    CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial • Metastases
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • tovecimig (CTX-009)
    over1year
    COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=84, Active, not recruiting, Compass Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    tovecimig (CTX-009)
    almost2years
    COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=84, Recruiting, Compass Therapeutics | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    tovecimig (CTX-009)
    almost2years
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=150, Recruiting, Compass Therapeutics | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jul 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    paclitaxel • tovecimig (CTX-009)
    almost2years
    A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients (clinicaltrials.gov)
    P1/2, N=92, Active, not recruiting, Handok Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial primary completion date: Aug 2024 --> Nov 2023
    Enrollment closed • Phase classification • Trial primary completion date • Combination therapy • Metastases
    |
    paclitaxel • irinotecan • tovecimig (CTX-009)
    almost2years
    A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002. (ASCO-GI 2024)
    Systemic chemotherapy usually begins with gemcitabine, platinum agents, and a checkpoint inhibitor followed by 5-FU and oxaliplatin, irinotecan or a taxane...150 patients will be randomized in a 2:1 ratio to receive either CTX-009 plus paclitaxel or paclitaxel alone...Key secondary objectives include overall survival, progression-free survival, and duration of response. Clinical trial information: 251040.
    Clinical • P2/3 data
    |
    NOTCH1 (Notch 1)
    |
    VEGFA overexpression
    |
    gemcitabine • paclitaxel • 5-fluorouracil • oxaliplatin • irinotecan • tovecimig (CTX-009)
    almost3years
    ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors—Colorectal Cancer Cohort (trial in progress). (ASCO-GI 2023)
    Up to 30 patients will be enrolled to each CRC cohort from approximately 8 sites in the US and will receive 3 mg/kg navicixizumab alone (Cohort A1) or in combination with irinotecan (180 mg/m2 on Days 1 and 15 of a 28-day cycle, Cohort A2). Secondary efficacy endpoints include overall survival, time to response, disease control rate, duration of response, and the relationship between antitumor activity of navicixizumab and Xerna TME Panel biomarker subtypes. Clinical trial information: NCT05453825.
    Combination therapy • P2 data • Clinical • Pan tumor • Metastases
    |
    Oncomap™ ExTra test • Xerna TME™ Panel
    |
    irinotecan • navicixizumab (OMP-305B83)